Shares of vTv Therapeutics Inc (NASDAQ:VTVT) crossed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $1.55 and traded as high as $1.41. vTv Therapeutics shares last traded at $1.40, with a volume of 5,500 shares trading hands.
A number of analysts have commented on VTVT shares. Northland Securities restated a “hold” rating and set a $3.00 price target on shares of vTv Therapeutics in a research note on Wednesday, February 27th. Zacks Investment Research lowered shares of vTv Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, May 2nd. ValuEngine upgraded shares of vTv Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, May 23rd. Finally, HC Wainwright reiterated a “buy” rating and issued a $5.00 target price on shares of vTv Therapeutics in a research note on Friday, June 7th.
The stock has a market cap of $68.94 million, a price-to-earnings ratio of -1.99 and a beta of -3.70.
In other news, major shareholder Ronald O. Perelman purchased 1,358,698 shares of the stock in a transaction dated Wednesday, May 15th. The shares were purchased at an average cost of $1.84 per share, with a total value of $2,500,004.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 1.70% of the company’s stock.
A number of institutional investors and hedge funds have recently made changes to their positions in VTVT. D. E. Shaw & Co. Inc. purchased a new stake in vTv Therapeutics in the fourth quarter valued at approximately $186,000. Barclays PLC grew its position in vTv Therapeutics by 366.7% during the fourth quarter. Barclays PLC now owns 28,000 shares of the biotechnology company’s stock valued at $74,000 after acquiring an additional 22,000 shares during the last quarter. Finally, Wedbush Securities Inc. bought a new position in vTv Therapeutics during the first quarter valued at approximately $30,000. 3.94% of the stock is currently owned by institutional investors and hedge funds.
vTv Therapeutics Company Profile (NASDAQ:VTVT)
vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase II/III clinical trials for the treatment of mild Alzheimer's disease.
See Also: QQQ ETF
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.